Centrexion
509 S Exeter Street #202,
Baltimore
Maryland
21202
United States
Tel: 410-522-8701
Website: http://centrexion.com/
Email: info@centrexion.com
About Centrexion
Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.YEAR FOUNDED:
December 2013
LEADERSHIP:
CEO: Jeffrey B. Kindler
Chief Veterinary Officer: Peter Hanson, DVM, Ph.D.
Chief Business Officer: Kerrie Brady, BPharm, MS, MBA
CFO: Gregg Beloff, J.D., MBA
CLINICAL TRIAL:
Please click here for clinical trial information.
33 articles about Centrexion
-
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
-
Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
10/29/2020
Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today announced that it has raised $40.5 million of cash via: Convertible security investments from Lilly and Exome Asset Management – each a new investor in Centrexion; Collaboration-related investment from
-
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
12/3/2019
Patent Underpins CNTX-4975 Formulation Technology and Provides Intellectual Property Protection into 2037
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
5/28/2019
Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain.
-
Eli Lilly announced it has inked a license agreement with Centrexion Therapeutics to acquire the exclusive global rights to CNTX-0290.
-
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting
10/16/2018
American College of Rheumatology and the Association of Rheumatology Health Professionals’ (ACR/ARHP) 2018 Annual Meeting taking place from October 19 – 24 in Chicago, Illinois.
-
Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
9/24/2018
Centrexion Therapeutics Corporation today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company.
-
Biotech Movers and Shakers Aug 20
8/20/2018
This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position. -
Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors
8/15/2018
Mr. Mendelson served as associate director for health at the Office of Management and Budget as part of the Clinton administration.
-
Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer
7/30/2018
Centrexion Therapeutics Corporation announced that Nick Harvey has been appointed Chief Financial Officer of the company.
-
Centrexion Therapeutics Selects Skyland Analytics' Skyland PIMS™ Software as their Data Repository for Manufacturing and Quality Compliance
6/18/2018
Skyland PIMS' cloud-based software will streamline management of critical data in their process development and manufacturing operations.
-
Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting
4/19/2018
Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 in healthy volunteers and Phase 2b efficacy and safety data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting
-
Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
2/21/2018
Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
-
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
1/16/2018
CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.
-
The Latest Biotech Startups to Watch
1/8/2018
A look at the latest startups that have emerged in 2018 so far. -
Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III.
-
Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017
10/30/2017
The presentations include 6-month data from the Phase 2b TRIUMPH study assessing the efficacy and safety of CNTX-4975.